Sunbelt Securities’s Recursion Pharmaceuticals RXRX Stock Holding History

Sunbelt Securities’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-92	Closed	-$449	–	2928
2025 Q3	$449	Hold	92	–	–	﹤0.01%	2248
2025 Q2	$622	Hold	92	–	–	﹤0.01%	1697
2025 Q1	$487	Hold	92	–	–	﹤0.01%	1700
2024 Q4	$623	Buy	+92	New	+$619	﹤0.01%	1701

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sunbelt Securities's RXRX Position: Q4 2025 in Review

Sunbelt Securities sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 92 shares — an estimated $449 sold.

Sunbelt Securities first reported a position in RXRX in Q4 2024 and held it in 4 quarters. The position peaked at $623 in Q4 2024. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

Sunbelt Securities reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Sunbelt Securities sold 92 Recursion Pharmaceuticals shares in Q4 2025, an estimated $449.
Sunbelt Securities first reported a position in Recursion Pharmaceuticals in Q4 2024 and held it in 4 quarters.
Sunbelt Securities's Recursion Pharmaceuticals position peaked at $623 in Q4 2024.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Sunbelt Securities's 13F filing for Q4 2025, filed 20 Feb 2026.